Investors / Biovision Ventures
Biovision Ventures
Venture capital
Biovision Ventures is a venture firm focused exclusively on life sciences and healthcare. It invests in early-stage companies and takes board positions as an active investor, typically leading or co-leading within a syndicate.
Invests inHealthcare & Biotech
In its own wordslife scienceshealthcaretherapeuticsbio-itdrug discoverymedical software
Your fit with Biovision Ventures
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsBiovision Ventures lists 14 checked portfolio companies on its own site and is named in 2 funding rounds. Its most frequent entry is Series A, 50% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 89% of its companies are based in United States. It invests most often alongside RV Invest, NEA and Pappas Capital.
Counts come from funding rounds that name Biovision Ventures, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Biovision Ventures' whole history. Rounds on record name 2 companies; its own site lists 14. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 50% |
| Series B | 50% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 1 | 0 |
| '25 | 0 | 0 |
| '26 | 1 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 36th | 14 companies |
| Recent activity | 59th | 1 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 85th | 14% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 42th | 2 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| RV Invest | 4 |
| NEA | 2 |
| Pappas Capital | 2 |
| 10VC | 1 |
| Alumni Ventures | 1 |
| Andreessen Horowitz | 1 |
| Aphelion Capital | 1 |
| Astellas Venture Management | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers14100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare Biovision Ventures head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Biovision Ventures| Date | Company | Stage |
|---|---|---|
| 8 Jan 2026 | Series B | |
| 9 Oct 2024 | Series A |
Round details for Biovision Ventures
Amounts, full round histories and every co-investor in Biovision Ventures' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
14 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Arda Therapeutics is taking aim at chronic diseases by eliminating the pathogenic cells that drive them. | Healthcare & Biotech | Oct 2024Series A | Page + round | |
| The company is undertaking a strategic transformation focused on building a high-value pipeline in neurology and oncology. | Healthcare & Biotech | Portfolio page | ||
| Contineum Therapeutics is pioneering new therapies for conditions at the intersection of inflammatory and fibrotic diseases. | Healthcare & Biotech | Portfolio page | ||
| Diagonal Therapeutics develops clustering antibodies to correct the root cause of genetic diseases | Healthcare & Biotech | Jan 2026Series B | Page + round | |
| Elucid offers a clinical platform for non-invasive CT plaque analysis for cardiologists and radiologists | Healthcare & Biotech | Portfolio page | ||
| Hawthorne Health conducts clinical trials in community settings and at patients' homes | Healthcare & Biotech | Portfolio page | ||
| The company provides clinical imaging services for every phase of a program, including centralized image management and expert radiological review | Healthcare & Biotech | Portfolio page | ||
| Immusoft engineers B cells as biofactories for therapeutic protein delivery | Healthcare & Biotech | Portfolio page | ||
| Pandica develops novel devices for the diagnosis and treatment of life-threatening conditions of gastrointestinal and pancreato-biliary systems. | Healthcare & Biotech | Portfolio page | ||
| Radar Therapeutics is pioneering a new treatment modality: precision-expressed mRNA-based therapeutics. | Healthcare & Biotech | Portfolio page | ||
| Solu Therapeutics is pioneering a new therapeutic modality to transform patient lives by developing a new type of antibody therapeutic | Healthcare & Biotech | Portfolio page | ||
| Sorriso Pharmaceuticals is developing novel oral antibodies to address unmet needs in immune-mediated disease. | Healthcare & Biotech | Portfolio page | ||
| Tune Therapeutics develops genetic tuning technology to control gene activity and reverse cellular dysfunction and disease | Healthcare & Biotech | Portfolio page | ||
| Walking Fish Therapeutics is rapidly advancing cell-based therapeutics to treat serious diseases, concentrating on oncology and regenerative therapies. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- biovision.vc
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 9 Oct 2024
- Companies checked
- 14
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Biovision Ventures' profile as data
Pull Biovision Ventures' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/biovision.vc
# also
GET /v1/firms/biovision.vc/portfolio
GET /v1/firms/biovision.vc/coinvestors
GET /v1/firms/biovision.vc/news